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Microscopic colitis (MC), comprising collagenous colitis (CC) and lymphocytic colitis (LC), is a common cause of chronic diarrhea.
Various immune cell infiltrations in the epithelium and lamina propria are seen in MC immunopathology. We compared gene and
protein expressions of different immune cell attracting chemokines and their receptors in colon biopsies from MC patients in
active disease or histopathological remission (CC/LC-HR) with controls, using qRT-PCR and Luminex, respectively. CC and LC
patients with active disease demonstrated a mixed chemokine profile with significantly enhanced gene and/or protein expressions
of the chemokines CCL2, CCL3, CCL4, CCL5, CCL7, CCL22, CXCL8, CXCL9, CXCL10, CXCL11, and CX
3
CL1 and the receptors
CCR2, CCR3, CCR4, CXCR1, CXCR2, and CX
3
CR1. Enhanced chemokine/chemokine receptor gene and protein levels in LC-HR
patients were similar to LC patients, whereas CC-HR patients demonstrated almost normalized levels. These findings expand the
current understanding of the involvement of various immune cells in MC immunopathology and endorse chemokines as potential
diagnostic markers as well as therapeutic candidates. Moreover, this study further supports the hypothesis that CC and LC are two
different entities due to differences in their immunoregulatory responses.
1. Introduction
Microscopic colitis (MC), comprising collagenous colitis
(CC) and lymphocytic colitis (LC), is characterized clinically
by chronic watery diarrhea, abdominal pain, and/or weight
loss.The diagnosis relies on typical histopathological features
that are observed upon microscopic examination: lympho-
cytic infiltration of the epithelium and lamina propria as well
as a damaged, flattened, and detached epithelial layer and in
CC a characteristic thickened subepithelial collagen layer [1–
4]. Biopsies from both LC and CC patients reveal a mixed
inflammatory cell infiltrate in lamina propria, including T
and B lymphocytes, plasma cells, eosinophils, neutrophils,
mast cells, and macrophages [5–9]. Although the etiology of
MC remains unclear, barrier dysfunction, increased numbers
of immune cells, and/or immune response to luminal agents
have all been suggested to be part of the pathogenesis [1].
Chemokines are small (∼8–14 kDa) secreted proteins that
orchestrate leukocyte migration by chemotaxis in home-
ostasis and inflammation [10]. Specificity in chemotaxis
depends on both differential expressions of chemokines and
their corresponding receptors expressed by leukocyte subsets
[11]. Hence, dysregulated expression of chemokines and/or
receptors may contribute to pathogenesis in different chronic
inflammatory disorders [12]. Therefore, our aim in this study
was to compare gene and protein expressions of a number of
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Figure 1: Summary of chemokines and their receptors investigated in this study. The chemokines interacting with their corresponding
receptors are indicated once for each receptor but are valid for all cell types expressing these receptors.
chemokines and their receptors, summarized in Figure 1, in
colon biopsies fromMC patients with active disease (CC/LC)
or those clinically active but in histopathological remission
(CC/LC-HR) with controls. To the best of our knowledge,
this is the first comprehensive study demonstrating increased
mucosal gene and protein expressions of immune cell attract-
ing chemokines and their receptors in CC and LC. LC-HR
patients showed similarities with LC patients in terms of
enhanced chemokine and receptor expression levels, whereas
CC-HR patients had normalized expressions. These results
contribute to the knowledge of MC immunopathology, a
subtler type of inflammatory bowel disease (IBD).
2. Materials and Methods
2.1. Patients. The MC patients underwent colonoscopy
because of watery diarrhea, abdominal pain, and/or weight
loss. Routine biopsy specimenswere obtained from the proxi-
mal, transverse, and distal colon for confirmation of diagnosis
through histopathological examination of paraffin embedded
slides by an experienced gastropathologist. Histopathological
criteria for CC were a diffusely distributed and thickened
subepithelial collagen layer (≥10 𝜇m), epithelial damage such
as flattening and detachment, inflammation in the lamina
propria with mainly mononuclear cells, and increased num-
bers of intraepithelial lymphocytes (IELs). Histopathological
criteria for LC were, in addition to epithelial damage and
inflammation in the lamina propria, ≥20 IELs per 100 surface
epithelial cells but with a normal collagen layer [1]. The
clinical characteristics of the patients and controls were
summarized in Table 1.
Four patients with an established diagnosis of CC and
six patients with LC no longer fulfilled the histopathological
criteria for MC despite clinical symptoms of the disease.
These patients were therefore categorized as clinically active
but histopathologically in remission (CC-HR/LC-HR) [13]
and were analyzed separately (Table 1).
In gene and protein expression analyses, two patients with
CC and two patients with LCwere treated with budesonide at
the time of colonoscopy, including only one patient having
budesonide treatment 3 days before the colonoscopy. In
protein expression analysis we included one more patient
with CC, who was on budesonide treatment. These patients
were identified in the graphs as circled symbols. We were
unable to detect any effects of budesonide on the parameters
tested.
Fourteen control individuals underwent colonoscopy due
to changes in bowel habits (𝑛 = 2), iron deficiency anemia
(𝑛 = 3), rectal bleeding (𝑛 = 2), follow-up after diverticulitis
(𝑛 = 1), hemorrhoids (𝑛 = 1), irritable bowel syndrome
(𝑛 = 1), colon cancer screening (𝑛 = 3), or abdominal
pain (𝑛 = 1). The colonoscopy was macroscopically normal
except for occasional diverticula in the left colon, and routine
biopsy specimens from ascending, transverse, and distal
colon revealed no pathological alterations.
Biopsy specimens for this study were obtained from the
proximal colonwith standard biopsy forceps andwere imme-
diately immersed in RNAlater (Ambicon, Life Technologies,
Foster City, CA, USA) and then stored at −80∘C for later
analysis.
2.2. RNA Isolation. Total RNA was isolated with miRNeasy
Kits (Qiagen, GmbH, Hilden, Germany) according to the
manufacturer’s protocol and was quantified using a
NanoDrop ND 1000 spectrophotometer (NanoDrop Tech-
nologies Inc., Wilmington, DE, USA).
Mediators of Inflammation 3
Table 1: Clinical characteristics of patients and controls.
CCa CC-HRb LCc LC-HRd Control
mRNA Protein mRNA Protein mRNA Protein mRNA Protein mRNA Protein
Number of patients 9 13 3 4 8 5 6 6 9 10
Male/female 1/8 2/11 0/3 0/4 0/8 0/5 0/6 0/6 6/3 5/5
Age (y) 66.7
e
(35–84)
62.5
(35–84)
55
(50–64)
57.3
(50–64)
69.1
(49–86)
74
(65–86)
61
(24–80)
57.8
(24–80)
61.1
(29–88)
53.4
(28–78)
Duration of disease (y) 6.7(0–17)
6.9
(0–17)
5
(1–9)
6
(1–9)
2.4
(0–7)
1.8
(0–6)
1.2
(0–3)
2.2
(0–7) n/a n/a
aCC: specimens from collagenous colitis; bCC-HR: specimens from clinically active CC patients in histopathological remission; cLC: specimens from
lymphocytic colitis; dLC-HR: specimens from clinically active LC patients in histopathological remission. eData are shown as mean (range).
2.3. Reverse Transcription and Quantitative Real Time Reverse
Transcription Polymerase Chain Reaction (qRT-PCR). All
products used in the reverse transcription and qRT-PCRs
were ordered from Applied Biosystems, Life Technologies
(Austin, TX, USA). cDNA transcription of 500 ng/𝜇L total
RNA was performed by High-Capacity cDNA Reverse
Transcription Kits according to the manufacturer’s protocol.
The following TaqMan primer-probe sets were used: CCL2/
MCP-1 (Hs00234140 m1), CCL3/MIP-1𝛼 (Hs00234142 m1),
CCL4/MIP-1𝛽 (Hs99999148 m1), CCL5/RANTES (Hs-
00174575 m1), CCL7/MCP-3 (Hs00171147 m1), CCL22/MDC
(Hs01574247 m1), CXCL8/IL-8 (Hs00174103), CXCL9/MIG
(Hs00171065 m1), CXCL10/IP-10 (Hs01124251 g1), CXCL11/
I-TAC (Hs04187682 g1), CX
3
CL1/Fractalkine (Hs00171086
m1), CCR1 (Hs00928897 s1), CCR2 (Hs00704702 s1),
CCR3 (Hs00266213 s1), CCR4 (Hs00747615 s1), CCR5 (Hs-
99999149 s1), CXCR1 (Hs01921207 s1), CXCR2 (Hs01891184
s1), CXCR3 (Hs01847760 s1), and CX
3
CR1 (Hs01922583 s1).
Normalization of qRT-PCR results was performed
using the mean of three housekeeping genes GAPDH
(Hs99999905 m1), GUSB (Hs99999908 m1), and 18S
(Hs99999901 s1). For gene expression assays, TaqMan Fast
Universal Master Mix was used with the thermal cycling
parameters suggested in the manufacturer’s protocol. The
samples were run in the GeneBio-rad CFX96 Touch Real-
Time PCR Detection System (Bio-rad Laboratories Inc.,
Hercules, CA, USA). Gene expressions were expressed
relative to the average of the housekeeping genes. The
comparative threshold cycle method was used to compare
control and patient results [14].
2.4. Protein Extraction and Chemokine Analysis. The mean
(±SEM) weight of biopsy specimens used for chemokine
quantification was 5.6 ± 1.5mg. The biopsies stored in
RNAlater were homogenized using Tissuelyser II (Qiagen,
GmbH, Hilden, Germany) at 25Hz for 5 times 1 minute
in RIPA buffer (Sigma Aldrich, Steinheim, Germany) con-
taining proteinase inhibitor cocktail (catalog number P8340,
Sigma Aldrich). The homogenization mixture was cen-
trifuged for 5min at 10,000 rpm, and the supernatant was
divided into aliquots and stored at −80∘C until further pro-
cessing. Tissue protein levels of CCL2, CCL3, CCL4, CCL7,
CXCL8, CXCL10, and CX
3
CL1 were analyzed in duplicate by
xMAP technology developed by Luminex (Austin, TX, USA).
The concentrations were determined using theMilliplexMap
Kit (catalog number SPR217) according to themanufacturer’s
instructions (Millipore, MA, USA). The levels of different
chemokines from MC and controls were expressed as pg/mg
tissue, according to a standard curve with known amounts of
each analyte (Millipore).
2.5. Statistical Analysis. Data values were compared accord-
ing to the nonparametric Mann-Whitney test with statistical
significance set at 𝑃 < 0.05 (GraphPad Prism 4, San Diego,
CA, USA). Statistical outliers were any points found below
first quartile (Q
1
) − 1.5 × interquartile range (IQR) and above
Q
3
+ 1.5 × IQR. When present they are marked as crosses
(X) in the graphs and excluded from the statistical analysis.
The different patient groups including CC and LC and
those in histopathological remission (CC-HR/LC-HR) were
compared to noninflamed control tissues. Also, patients with
active disease or with the same disease in histopathological
remission were compared to each other.
3. Results
3.1. Increased Expressions of the Th1 and CD8+ T Cell-
Associated Chemokines CXCL9, CXCL10, CXCL11, and
CX
3
CL1 in MC Patients. CXCL9, CXCL10, CXCL11, and
CX
3
CL1 are important chemokines in Th1 and CD8+ T cell
recruitment [15, 16]. Significantly increased gene expressions
of CXCL9, CXCL10, CXCL11, and CX
3
CL1 were detected
in CC patients compared to both controls and CC-HR
patients (Figures 2(a)–2(d)). CC-HR patients also had
decreased CXCL10 gene expression compared to controls
(Figure 2(b)). Likewise, LC patients showed significantly
enhanced CXCL9, CXCL10, CXCL11, and CX
3
CL1 gene
expressions compared to controls (Figures 2(a)–2(d)). The
enhanced gene expression levels of CXCL9, CXCL11, and
CX
3
CL1 in LC-HR patients compared to controls indicate
similarities with LC patients (Figures 2(a), 2(c), and 2(d)).
Protein expression of CXCL10 was enhanced in CC
patients compared to controls and CC-HR patients (Fig-
ure 2(e)), in line with CXCL10 gene expression (Figure 2(b)).
Likewise, LC patients had enhanced CXCL10 protein levels
in comparison with both controls and LC-HR patients (Fig-
ure 2(e)). CX
3
CL1 protein level was significantly increased in
LC patients only compared to controls (Figure 2(f)).
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Figure 2: Gene and protein expressions of the Th1 and CD8+ T cell recruiting chemokines CXCL9, CXCL10, CXCL11, and CX
3
CL1. Each
symbol represents one patient and themedians of the values are depicted as a line. Statistical outliers aremarked as crosses (X) and budesonide
treated patients are encircled. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 ≤ 0.001 versus controls, #𝑃 < 0.05, ##𝑃 < 0.01 versus CC-HR, and ¤𝑃 < 0.05,
¤¤
𝑃 < 0.01 versus LC-HR.
3.2. Gene Expression of CX
3
CR1 but not CXCR3 Was Upreg-
ulated in MC Patients. CXCL9, CXCL10, and CXCL11 bind
to a common receptor, CXCR3 [15], whereas CX
3
CL1 only
interacts with CX
3
CR1 [16]. CX
3
CR1 gene expression was
significantly increased in CC, CC-HR, and LC-HR patients
compared to controls (Figure 3(a)).The only significant alter-
ation in CXCR3 gene expression was diminished expression
in CC-HR patients compared to CC patients (Figure 3(b))
as well as a trend towards decreased expression compared to
controls (𝑃 = 0.06, Figure 3(b)).
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Figure 3: Relative gene expressions of the chemokine receptors CX
3
CR1 and CXCR3. Each symbol represents one patient, and the medians
are depicted as a line. Statistical outliers are marked as crosses (X) and budesonide treated patients are encircled. ∗𝑃 < 0.05 versus controls
and #𝑃 < 0.05 versus CC-HR.
3.3. The Neutrophil Recruiting CXCL8 and Its Receptors
CXCR1 and CXCR2 Showed Enhanced Gene and Protein
Levels in MC Patients. Gene and protein expressions of
CXCL8 were significantly increased in both CC and LC
patients compared to controls, with the highest expressions
recorded in CC patients (Figures 4(a) and 4(b)). In addition,
CC patients showed significantly increased CXCL8 gene
expression compared to CC-HR patients (Figure 4(a)) as
well as a trend towards increased protein levels (𝑃 = 0.06,
Figure 4(b)). The two receptors, CXCR1 and CXCR2, showed
significantly increased gene expressions in all MC patient
groups compared to controls (Figures 4(c) and 4(d)).
3.4. Enhanced Gene and Protein Levels of CCL2, CCL3,
CCL4, CCL7, and CCL22 in MC Patients. CCL2, CCL3,
CCL4, CCL5, CCL7, and CCL22 are pleiotropic chemokines
attracting Th1, Th2, regulatory T (Treg) cells, neutrophils,
eosinophils, and/or macrophages [16–20].
CCL2 showed increased gene aswell as protein expression
inCC, LC, andLC-HRpatients compared to controls (Figures
5(a) and 5(b)). CC-HR patients showed intermediate levels
of CCL2 protein, being significantly increased compared to
controls but significantly decreased compared to CC patients
(Figure 5(b)).
CCL3 showed a trend towards increased gene expres-
sion (𝑃 = 0.06, Figure 5(c)) and significantly increased
protein levels (Figure 5(d)) in CC patients compared to
controls. CC-HR patients demonstrated diminished CCL3
gene expression compared to controls (Figure 5(c)) but no
change in protein levels (Figure 5(d)). Both gene and protein
expressions of CCL3 in LC patients were increased compared
to controls (Figures 5(c) and 5(d)). CCL3 protein levels
were also enhanced in LC-HR patients compared to controls
(Figure 5(d)).
CCL4 also showed enhanced gene and protein expres-
sions in both CC and LC patients compared to controls
(Figures 5(e) and 5(f)), whereas CC and LC patients in
histopathological remission (CC/LC-HR) had normalized
CCL4 gene and protein expressions (Figures 5(e) and 5(f)).
Eosinophils, Th1, and Th2 cells are recruited by CCL5
[18–20], which was significantly increased in LC patients
compared to both controls and LC-HR patients (Figure 6(a)).
CCL7 did not show significant changes in gene expression
in any group of MC patients (data was not shown), whereas
significantly increased protein expressionwas detected in LC-
HR patients but not in any other patient group compared to
controls (Figure 6(b)).
As opposed to CCL7, CCL22 gene expression was signifi-
cantly increased in CC, LC, and LC-HR patients compared
to controls (Figure 6(c)). In contrast, CC-HR patients had
significantly decreased gene expression compared to CC
patients, which was not different from the levels in controls
(Figure 6(c)).
3.5. Increased Gene Expressions of Chemokine Receptors
CCR2, CCR3, and CCR4 in MC. CCR2 binds CCL2, CCL5,
and CCL7 and is expressed on neutrophils, eosinophils,
macrophages, Th1, Th2, and Treg cells [21, 22]. It showed
increased gene expression in CC patients only compared to
controls (Figure 7(a)). In contrast, CCR3, binding CCL4,
CCL5, and CCL7 and being expressed on neutrophils,
eosinophils, Treg,Th1, andTh2cells [18, 20, 23], had increased
gene expression in all MC patient subgroups compared to
controls (Figure 7(b)).
CCR4, binding to CCL22 and being found on macro-
phages, eosinophils, Th2, and Treg cells [18, 20], was signifi-
cantly upregulated in CC, LC, and LC-HR patients compared
to controls (Figure 7(c)). In CC patients CCL22 gene expres-
sion was also significantly upregulated compared to CC-HR
patients (Figure 7(c)).
In contrast, neither CCR1 nor CCR5 showed any signifi-
cant changes in gene expression (data was not shown).
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Figure 4: Relative gene and protein expressions of the neutrophil recruiting chemokine CXCL8, as well as gene expression of its receptors
CXCR1 and CXCR2. Each symbol represents one patient and the medians of the values are depicted as a line. Statistical outliers are marked as
crosses (X) and budesonide treated patients are encircled. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 ≤ 0.001 versus controls and #𝑃 < 0.05, ##𝑃 < 0.01
versus CC-HR.
4. Discussion
Although clinical and epidemiological data on MC are
emerging the pathophysiology is still unclear and the searches
for triggering factors and underlying dysfunctions in the
mucosal immune system are still in an early stage [1–3].
Both CC and LC show infiltration primarily of T cells
but also plasma cells, eosinophils, mast cells, macrophages,
and neutrophils [5–8], which may be recruited by different
chemokines and their receptors.The chemokines investigated
in this study are all secreted from different cell types:
CCL2, CCL3, CCL4, CCL5, CCL7, CXCL8, CXCL9, CXCL10,
CXCL11, and CX
3
CL1 are secreted by colon epithelial cells
[11, 21, 24, 25], whereas CCL22 is expressed by macrophages,
mast cells, and dendritic cells [26, 27]. In addition, these
chemokines can also be secreted by immune cells in the
lamina propria, for example, macrophages (CCL2, CCL5,
CCL22, CXCL8, and CXCL10), mast cells (CCL2, CCL5,
and CCL22), eosinophils (CCL2, CCL5, and CCL7), and
neutrophils (CXCL8 and CXCL10) [18, 21, 26, 28–32]. The
gene and/or protein expressions of all these chemokines
have been demonstrated to be increased in Crohn’s disease
(CD) and ulcerative colitis (UC) patients [21, 24, 33, 34].
However, to the best of our knowledge, there is only one
study analyzing chemokine expression in MC patients, and
that studywas limited to observations of CXCL9 andCXCL10
in three LC patients compared to controls [35].Therefore, we
focused on chemokines and their receptors possibly involved
in immune cell infiltration inMC immunopathology in order
to increase our understanding of the disease mechanism(s)
and eventually reveal possible therapeutic candidates.
Enhanced CXCL9, CXCL10, CXCL11, CX
3
CL1, and
CX
3
CR1 gene and protein levels are likely involved in the
CD8+ T cell infiltration [16, 33, 36] in the intraepithelial
compartment and lamina propria of both CC and LC patients
previously reported by us [9, 13]. These chemokines are also
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Figure 5: Relative gene and protein expressions of chemokines mediating recruitment of eosinophils, neutrophils, macrophages, Treg, Th1,
and/orTh2 cells. Each symbol represents one patient and the medians are depicted as a line. Statistical outliers are marked as crosses (X) and
budesonide treated patients are encircled. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 ≤ 0.001 versus controls, #𝑃 < 0.05 versus CC-HR, and ¤𝑃 < 0.05,
¤¤
𝑃 < 0.01 versus LC-HR.
associated with Th1 cell recruitment. However, we observed
increased numbers of CD8+ T cells only in MC patients
and decreased numbers of CD4+ T cells. Therefore, these
chemokines are more likely involved in CD8+ T cell recruit-
ment inMC. IFN-𝛾 is inducingCXCL9,CXCL10, andCXCL11
expressions, and we previously reported upregulated IFN-𝛾
mRNA levels in CC, LC, and LC-HR patients, with normal
levels in CC-HR patients [37]. These results corroborate our
present results demonstrating enhanced expression of these
chemokines in CC, LC, and LC-HR patients with normalized
levels in CC-HR patients.
Enhanced gene and protein expressions of CXCL8 and
its receptors CXCR1 and CXCR2 in MC patients suggest an
important role for neutrophils, previously observed in the
lamina propria of MC patients [3, 16, 19]. The significant
upregulation of CXCR1 and CXCR2 gene expressions also in
CC-HR and LC-HR patients could be related to neutrophil
recruitment due to ongoing contact with the gut microbiota,
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Figure 6: Relative gene and protein expressions of CC chemokines involved in recruitment of eosinophils, neutrophils, macrophages, Treg,
Th1, and/or Th2 cells. Each symbol represents one patient and the medians are depicted as a line. Statistical outliers are marked as crosses
(X) and budesonide treated patients are encircled. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 ≤ 0.001 versus controls, #𝑃 < 0.05 versus CC-HR, and
¤
𝑃 < 0.05 versus LC-HR.
as these patients still have histopathological evidence of
inflammation, although not fulfilling the criteria for CC/LC
diagnosis (gastropathologist Agnes Hegedus, personal com-
munication).
In IBD patients increased CCL2 expression has been
correlated with disease activity, mainly in areas of epithelial
cell damage [24]. Our findings of enhanced CCL2 gene
and protein expressions in both active and histopathological
remission patients may likewise correlate with epithelial cell
damage in MC, similar to IBD immunopathology [3].
Although CCL3, CCL4, CCL5, CCL7, and CCL22 attract
many different cell types such as eosinophils, neutrophils,
macrophages, Treg, Th1, and/or Th2 cells [16, 18, 19],
decreased numbers of CD4+ T cells detected by us in MC
patients [9, 13], these chemokines are likely involved mainly
in eosinophil, neutrophil, and macrophage recruitment.
Eosinophil infiltration in CC patients has previously been
demonstrated [7, 38, 39]. Because of high levels of these
chemokines also in LC and LC-HR patients, eosinophils may
be involved also in LC immunopathology.
Infiltration of inflammatorymacrophages, with their high
IL-23 production [40], has been suggested as part of IBD
immunopathology [41–43]. The present data, together with
our previously reported enhanced gene expression of IL-
23, may also suggest an important role of macrophages
in MC immunopathology [37]. Accordingly, CCR2, CCR3,
and CCR4 are predominantly expressed on eosinophils and
macrophages [16, 20, 44]. However, Treg cells, found in
increased amounts in lamina propria of MC patients [45],
may be another source of these chemokine receptors [16, 20].
A potential limitation of this study is the small cohort of
MC patients collected. However, as the majority of param-
eters investigated show statistically significant changes, we
believe that the small cohort is not an obstacle in this study.
In addition, we chose to analyze patients with clinical symp-
toms but not fulfilling the histological criteria for CC/LC
separately, increasing our knowledge about these subgroups.
MC can only be diagnosed upon histopathological exami-
nation and patients with an MC diagnosis usually do not
undergo repeated colonoscopies. Nevertheless, as there is still
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Figure 7: Relative gene expression of the chemokine receptors CCR2, CCR3, and CCR4. Each symbol represents one patient and themedians
are depicted as a line. Statistical outliers are marked as crosses (X) and budesonide treated patients are encircled. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
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no cure for MC and the medications only relieve disease
symptoms, studies like this one are necessary to increase the
understanding of the immunopathogenesis and to find new
avenues for treatment. This study also further supports the
legitimacy of MC as a “model” to study the role of changes
in immune regulation and basic pathophysiology of IBD,
where MC patients may reveal important immunoregulatory
mechanisms.
5. Conclusion
One of the diagnostic criteria of CC and LC is increased
numbers of lymphocytes in both the epithelium and the
lamina propria, but infiltration of additional immune cells
such as neutrophils, eosinophils, and macrophages is also
observed. We found enhanced mRNA and protein expres-
sions of a mixed profile of chemokines and their receptors
in CC and LC patients. Interestingly, LC-HR showed similar-
ities with LC patients, whereas CC-HR patients had almost
normalized expression patterns. The contrasting expression
patterns in CC and LC patients in histopathological remis-
sion (CC/LC-HR) further support the hypothesis of CC
and LC being different entities. These results contribute
to the knowledge of MC immunopathology by suggesting
important immunoregulatory roles of chemokines and their
receptors involved in recruitment of CD8+ T cells, Treg cells,
neutrophils, eosinophils, and macrophages. The parameters
investigated in this study might be important possible future
therapeutic targets to interfere with cell recruitments in MC
patients.
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